FDMT Q1 2025 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14,000-50.0% YoY

Gross Profit

$14,000100.0% margin

Operating Income

-$54M-383007.1% margin

Net Income

-$48M-342657.1% margin

EPS (Diluted)

$-0.86

QoQ Revenue Growth

+1300.0%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$48M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$516M

Total Liabilities

$46M

Stockholders' Equity

$470M

Cash & Equivalents

$134M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14,000	$28,000	-50.0%
Gross Profit	$14,000	-$28M	+100.1%
Operating Income	-$54M	-$38M	-40.6%
Net Income	-$48M	-$32M	-48.1%

Revenue Segments

Collaboration And License Revenue

$14,000100%